Main Products/ Services/ Pipelines & Platforms
From development candidates to clinical PoC is the decree of Anbogen Therapeutics (ABT). Anbogen aimed at developing precision oncology medicines by targeting driver genes in cancers with unmet therapeutic needs. i. ABT-101 targets to treat NSCLC patients harboring HER2e20i. ABT-101 holds the best-in-its-class drug premises owing to early safety data in human and a series of head-to-head studies with competitor compounds. Taiwan Food and Drug Administration (TFDA) has approved a Phase 1b/2 clinical trial for ABT-101 to treat NSCLC with HER2e20i. ii. ABT-201, targeting KRAS, is superior to sotorasib with respect to its enzyme inhibitory capability toward KRASG12C. iii. In accordance to results from a completed Phase 1 trial, ABT-301, a histone deacetylase inhibitor (HDACi), has the most assuring safety/PK profile among its class. Phase 2 trials will be focusing on assessing the ability of ABT-301 to enhance current therapeutics in cancers with biomarkers reflecting pathologic aberrations amenable to ABT-301 intervention.
Collaborative R&D: ▪ Academia Sinica ▪ Taipei Medical University
John T.-A. Hsu
Chairman & C.E.O.